

## Index

- A1C, **S14–S15, S61–S63**. *see also* glycemic targets  
 advantages of, S15  
 age and, S15  
 cardiovascular disease and, S64, S65  
 in children and adolescents, S20, S62, S151, S156  
 continuous glucose monitoring  
 reduction of, S76  
 discharge planning, S178–S179  
 ethnic variability in, S15, S62  
 glucose assessment, S62–S63  
 goals, S63–S64  
 goals, setting/modifying, S64–S66  
 hemoglobinopathies, S14, S15  
 HIV and, S41  
 limitations of, S62  
 microvascular complications and, S63–S65  
 in older adults, S141, S142  
 other conditions affecting, S15  
 performance of, S14–S15  
 physical activity benefits, S52  
 prediabetes, S17  
 pregnancy values, S14, S15, S166, S167  
 race/ethnicity, S15  
 recommendations, S14, S61, S63  
 testing frequency, S61–S62
- acarbose, S96
- ACCORD BP trial, S104–S106
- ACCORD MIND trial, S140
- ACCORD study, S40, S64, S65, S67, S127
- ACE inhibitors  
 children and adolescents, S153, S154  
 chronic kidney disease, S128–S129  
 hypertension, S106–S108  
 pregnancy, S169  
 retinopathy, S131
- acute kidney injury, S126
- ADA evidence-grading system, **S2**
- ADAG study, S62, S66
- ADA statements, S1
- adolescents. *see* children and adolescents
- ADVANCE BP trial, S105
- ADVANCE study, S64, S65, S67
- advocacy position statements, S6, **S182–S183**
- aerobic exercise, S52
- Affordable Care Act, S9, S160
- African Americans  
 A1C as predictive in, S17  
 A1C variability in, S15, S52, S62  
 BMI cut point, S20  
 exercise targets in, S52  
 food insecurity in, S10  
 hemoglobinopathies in, S15  
 hypoglycemia in, S67  
 idiopathic type 1 diabetes in, S16  
 risk-based screening, S18
- agave syrup, S51
- age, S15, S20
- $\alpha$ -glucosidase inhibitors, S31, S96
- AIM-HIGH trial, S112
- albiglutide, S116
- alcohol, S49, S51
- alogliptin, S96, S117, S118, S176
- American Indians, S18
- amylin mimetics, S83, S96
- angiotensin receptor blockers (ARBs)  
 children and adolescents, S153, S154  
 chronic kidney disease, S128–S129  
 hypertension, S106–S108  
 pregnancy, S169  
 retinopathy, S131
- anorexia nervosa, S144, S145
- anticholinergics, S83
- anticonvulsants, S83
- antidepressants, S83
- antihistamines, S83
- antihyperglycemics  
 cardiovascular disease, S115–S119  
 heart failure, S118  
 hospital care, **S175–S176**  
 obesity management, S83  
 type 2 diabetes, S92, S93
- antihypertensives  
 cardiovascular disease, S104, S106–S108  
 chronic kidney disease, S128  
 pregnancy, S169
- antioxidant supplementation, S51
- antiplatelet agents, S113–S114
- antipsychotics, S83
- antiretroviral (ARV) therapies, S41
- anti-VEGF, S129–S131
- anxiety disorders evaluation, S42, S55
- ARRIVE trial, S113
- ASCEND trial, S113, S114
- Asians Americans  
 BMI cut point, S17, S20  
 idiopathic type 1 diabetes in, S16  
 metabolic surgery, S85, S86  
 prediabetes/type 2 criteria, S18  
 risk-based screening, S18, S19
- Aspart, S97
- Aspart 70/30, S97
- ASPIRE study, S76
- aspirin  
 cardiovascular disease and, S113–S114  
 preeclampsia, S167–S169  
 resistance, S114  
 retinopathy and, S129
- ASPREE trial, S113
- assisted living facilities, S144, S145
- atorvastatin, S111
- autoimmune diseases, S39, S152
- automated insulin delivery, **S77**
- autonomic neuropathy  
 cardiac, S131, S132  
 diagnosis, S132  
 genitourinary, S132  
 glycemic control, S132  
 physical activity and, S53  
 pre-exercise evaluation, S52–S53  
 prevention, S131  
 screening, S131  
 treatment, S131, S132
- bariatric surgery referrals, S55
- BARI 2D trial, S132
- basal insulin analogs, S97–S99
- bedside blood glucose monitoring, **S175**
- behavioral therapy, **S82–S83**
- $\beta$ -blockers, S114
- beverage consumption, S5
- biguanides, S96
- bile acid sequestrants, S96
- blood glucose meter accuracy, S74
- blood pressure control. *see* hypertension
- blood pressure targets, S104
- BMI, ethnicity and, S17, S20
- board certified-advanced diabetes management (BC-ADM), S47
- bromocriptine, S96
- canagliflozin, S96, S98, S115–S116, S128
- cancer evaluation, S39
- CANVAS-Renal (CANVAS-R) trial, S115–S118
- CANVAS trial, S115–S119, S127, S128
- carbohydrates, S49, S50
- cardiovascular disease, **S103–S119**  
 A1C and, S64, S65  
 antihyperglycemics, S115–S119  
 antiplatelet agents, S113–S114  
 atherosclerotic, defined, S103  
 atherosclerotic, pharmacology in  
 type 2, S92, S98  
 cardiac testing, S114–S115  
 children and adolescents, S153–S155, S159  
 chronic kidney disease and, S128–S129  
 fats (dietary) and, S51  
 heart failure, S103, S114, S118–S119  
 hypertension, **S104–S113**  
 lifestyle interventions, S115  
 obesity management and, S82  
 pharmacology, S115–S119  
 pharmacology outcomes, S98  
 physical activity benefits, S52  
 prevention of, S31  
 primary prevention/aspirin, S113–S114  
 primary prevention/statins, S110  
 recommendations, S114  
 revisions summary, S5  
 risk assessment, S36, S103–S104  
 risk factors, S17, S20, S66  
 screening, S114, S115  
 secondary prevention/statins, S111  
 statins, S109–S113  
 stroke. *see* stroke  
 treatment, S114
- care delivery systems  
 Affordable Care Act, S9, S160  
 background, **S8**  
 care team, S8  
 chronic care model, **S8–S9**, S34  
 social context in, **S9–S10**  
 system-level improvement strategies, S8  
 telemedicine, S4, S5, S8–S9, S31, S129
- carotene, S51
- Caucasians

- A1C/mean glucose levels in, S52
- BMI cut points in, S20
- exercise levels in, S52
- hemoglobinopathies in, S15
- celiac disease, S152–S153
- certified diabetes educator (CDE), S47
- CGM. *see* continuous glucose monitoring (CGM)
- Charcot foot, S134
- child care/school, S150
- children and adolescents, **S148–S160**
  - A1C targets in, S151, S156
  - A1C validity in, S20, S62
  - autoimmune conditions in, S152
  - cardiac function testing, S159
  - cardiovascular risk factor management, S153–S155
  - celiac disease, S152–S153
  - complications prevention/management, S158–S160
  - continuous glucose monitoring in, S149, S151
  - diabetic ketoacidosis in, S149, S156, S157
  - DSMES, S149
  - dyslipidemia, S153–S154, S159
  - eating disorders in, S151
  - glycemic control/type 1, S151–S152
  - glycemic control/type 2, S156–S157
  - hypertension, S153
  - hypoglycemia in, S67
  - immune-mediated diabetes, S16
  - immunizations, S36
  - insulin pumps, S72–S73
  - lifestyle management, S156
  - metabolic surgery, S158
  - monogenic diabetes in, S25
  - nephropathy, S154
  - neuropathy, S155, S158
  - new-onset management algorithm, S157
  - nutrition therapy, S149, S156
  - obesity management, S150, S155, S156
  - pediatric to adult care transition, S160
  - pharmacology, S156–S158
  - physical activity/exercise, S51, S52, S149–S150, S156
  - preconception counseling, S150, S151
  - psychosocial issues, S150–S151, S159–S160
  - real-time CGM in, S75
  - retinopathy, S154–S155, S158–S159
  - revisions summary, S6
  - school/child care, S150
  - shared decision making, S150–S151
  - smoking, S154
  - thyroid disease, S152
  - type 2 diabetes in, S17, S18, **S155–S160**
  - type 1 diabetes in, S13–S14, **S148–S155**
- chronic care model, **S8–S9**, S34
- chronic kidney disease, **S124–S129**
  - acute kidney injury, S126
  - albuminuria screening, S125
  - albuminuria treatment, S128
  - antihypertensives, S128
  - cardiovascular disease and, S128–S129
  - children and adolescents, S154, S158–S159
  - complications of, S126
  - diagnosis of, S125
  - eGFR assessment, S125
  - epidemiology, S125
  - glucose-lowering medications, renal effects, S127
  - glycemic targets, S127
  - hypertension and, S124, S128–S129
  - nutrition therapy, S50, S53, S124, S127
  - pharmacology, S92, S97, S125, S127–S128
  - recommendations, S124–S125
  - referrals, S129
  - renal replacement treatment, S125, S129
  - screening, S124
  - staging of, S125–S126
  - surveillance, S126–S127
  - treatment, S124–S129
- CKD. *see* chronic kidney disease
- classification, S4, **S13–S14**
- clopidogrel, S113, S114
- closed-loop pump system, S91
- clozapine, S83
- cognitive impairment/dementia
  - evaluation, S39–S40
  - older adults, **S140**
  - risk factors, S67
  - statins and, S113
- colesevelam, S96
- community health workers, S10
- community screening, S20
- community support, S10
- comorbidities, S4, S36, **S39–S43**
- concentrated human regular insulin, S97, S99
- consensus reports, S1–S2
- contact dermatitis, S77
- continuous glucose monitoring (CGM), **S74–S77**
  - accuracy, S74, S75
  - A1C measurement with, S15
  - A1C reduction, S76
  - A1C testing and, S62
  - basal insulin/oral agents, S73–S74
  - children and adolescents, S149, S151
  - as complementary method, S73
  - flash, S76–S77
  - function, applications of, S75
  - glucose assessment, S62–S63
  - glycemic control impacts, S75
  - hospital care, S175
  - hypoglycemia impacts, S67, S75, S76
  - intensive insulin regimens, S73
  - optimization, S73
  - pregnancy, S169
  - real-time, S75–S76
  - recommendations, S74–S76
- continuous subcutaneous insulin injection (CSII), S72–S73
- contraception, S170
- counterfeit strips, S74
- CREDENCE trial, S128
- CVD. *see* cardiovascular disease
- cystic fibrosis, S13
- cystic fibrosis–related diabetes, **S23**
- DAMOCLES trial, S135
- dapagliflozin, S96, S128
- Da Qing Diabetes Prevention Study, S30
- DASH diet, S48, S109
- degludec, S97
- dental care, S20, S41
- depression evaluation, S42, S55
- detemir, S97
- Diabetes Control and Complications Trial (DCCT) trial, S65, S66, S67, S72, S91, S127, S140, S152
- diabetes distress, S54–S55
- Diabetes Prevention Program (DPP), S17, S29, S30, S31
- Diabetes Prevention Program Outcomes Study (DPPOS), S30, S51, S96
- Diabetes Prevention Recognition Program (DPRP), S31
- diabetes self-management education and support (DSMES), S9, S10
  - benefits of, S47
  - children and adolescents, S149
  - older adults, S141
  - principles of, **S46–S47**
  - psychosocial issues and, S54
  - recommendations, **S32**
  - reimbursement, S47
  - social determinants of health and, S9, S10
- diabetic ketoacidosis
  - in children and adolescents, S149, S156, S157
  - epidemiology, S13–S14
  - glycemic targets and, S68
  - hospital care, S178
  - nutrition therapy, S48, S50
  - pregnancy, S169
  - as pump complication, S72, S73
  - referrals, S55
  - risk factors, S16
  - in type 2 diabetes, S18
- diabetic kidney disease. *see* chronic kidney disease
- diabetic macular edema, S129, S131
- diabetic retinopathy. *see* retinopathy
- Diabetic Retinopathy Study (DRS), S130–S131
- diagnosis
  - A1C. *see* A1C
  - CFRD, **S23**
  - community screening, S20
  - confirming, S15–S16
  - criteria, S15
  - fasting plasma glucose (FPG), S14, S15, S20, S23
  - IFG, S17
  - MODY, S13, **S25**
  - monogenic diabetes syndromes, S13, **S24–S25**
  - neonatal diabetes, S24, **S25**
  - one-step strategy, GDM, S21–S22
  - oral glucose tolerance test (OGTT), S14, S20, S22
  - posttransplantation diabetes mellitus, **S23–S24**
  - revisions summary, S4
  - testing interval, S20
  - 2-h plasma glucose (2-h PG), S14, S15
  - two-step strategy, GDM, S21, S22
  - type 1 diabetes, S15, **S16–S17**
  - type 2 diabetes, **S17–S20**
- DIAMOND study, S76
- Dietary Reference Intakes (DRI), S168
- discharge planning, S178–S179

- disordered eating behavior evaluation, S42–S43
- DKA. *see* diabetic ketoacidosis
- dopamine-2 agonists, S96
- DPP-4 inhibitors
- in combination therapy, S93–S94, S97–S98
  - costs, S96
  - heart failure, S118
  - hospital care, S176
  - indications, considerations, S93
  - older patients, S143–S145
  - in renal transplant recipients, S24
- dulaglutide, S96
- duloxetine, S132
- dumping syndrome, S86
- e-cigarettes, S5, S6, **S53–S54**, S154
- economic costs of diabetes, S8
- EDIC study, S64–S67, S127
- ELIXA trial, S116–S118
- empagliflozin, S96, S98, S115, S116, S119, S128
- EMPA-REG OUTCOME trial, S115, S117–S119, S127, S128
- end-of-life/palliative care, S141, S144, **S146**
- enteral/parenteral feedings, S177
- eplerenone, S129
- erectile dysfunction, S133
- ertugliflozin, S96
- erythropoietin therapy, S15
- ETDRS, S130–S131
- ethnicity, S15, S20, S62. *see also* specific ethnicities
- evolocumab, S111
- EXAMINE trial, S117, S118
- Exenatide, Exenatide ER, S96
- exercise. *see* physical activity
- EXSCEL trial, S116–S118
- eye disease. *see* diabetic retinopathy
- ezetimibe, S111, S113
- fasting plasma glucose (FPG), S14, S15, S20, S23
- fats (dietary), S49–S51
- fenofibrate, S112
- fibrates, S112
- finerenone, S129
- Finland study, S16
- Finnish Diabetes Prevention Study, S30
- flash CGM, S76–S77
- food insecurity, S10
- foot care
- hyperbaric oxygen therapy, S134–S135
  - infections, S134
  - loss of protective sensation, S131, S134
  - neuropathy, **S133–S135**
  - patient education, S134
  - peripheral arterial disease, S133, S134
  - recommendations, S133
  - revisions summary, S5
  - treatment, S134
  - ulcers/amputations risk, S133–S134
- footwear, S134
- FOURIER trial, S111
- fractures, S40–S41
- frailty, S141–S142
- FRAX score, S41
- gabapentin, S5, S83
- gastrointestinal neuropathy, S132
- gastroparesis, S133
- genitourinary autonomic neuropathy, S132
- German study, S16
- gestational diabetes mellitus, S6, S13, **S20–S23**, S76, **S167–S170**
- GI surgery. *see* metabolic surgery
- glargine, glargine biosimilar, S97
- glimepiride, S96
- glipizide, S96
- GLP-1 receptor agonists
- cardiovascular disease outcomes, S65, S98, S114, S116
  - in CKD, S127, S128
  - in combination therapy, S93–S94, S97–S99
  - costs, S95, S97
  - heart failure, S118–S119
  - hospital care, S176
  - indications, considerations, S93
  - obesity management, S85
  - older patients, S143–S145
  - stroke and, S116
  - type 1 diabetes, S92
  - type 2 diabetes prevention/delay, S31
- glucagon, S66–S68
- glucocorticoids, S83, S177
- glucose oxidase systems, S74
- glulisine, S97
- gluten-free diets, S152, S153
- glyburide, S96, S167
- glycemic index/glycemic load, S50
- glycemic targets, **S61–S68**. *see also* A1C
- cardiovascular disease and, S64, S65
  - continuous glucose monitoring impacts, S75
  - evaluation of, S36, S39, **S61–S63**
  - glucose assessment, S62–S63
  - hospital care, **S174–S175**
  - intercurrent illness and, S68
  - management algorithm, S35
  - moderate vs. tight control, S174–S175
  - nonpregnant adults, S66
  - physical activity and, S52
  - in pregnancy, **S166–S167**, S169
  - preprandial, S67
  - revisions summary, S5
- G6PD deficiency, S4, S14, S15
- HAPO study, S21, S167
- Harmony Outcomes trial, S116
- hearing impairment evaluation, S41
- hemodialysis, S15
- hemoglobinopathies, S14, S15
- hepatitis B vaccine, S36, S38–S39, S127
- herbal supplements, S49, S51
- Hispanics. *see* Latinos
- HIV evaluation, S41
- homelessness, S10
- honey, S51
- hospital care, **S173–S179**
- admission considerations, S173–S174
  - admission/readmission prevention, **S179**
  - antihyperglycemics, **S175–S176**
  - bedside blood glucose monitoring, **S175**
- continuous glucose monitoring, S175
- delivery standards, **S173–S174**
- diabetes care providers in, S174
- diabetic ketoacidosis, S178
- discharge planning, S178–S179
- enteral/parenteral feedings, S177
- glucocorticoid therapy, S177
- glucose abnormalities definitions, S174
- glycemic targets, **S174–S175**
- hyperglycemia management, S24
- hyperosmolar hyperglycemic state, S178
- hypoglycemia, **S176–S177**
- insulin, IV to subcutaneous transition, S176
- insulin therapy, S174–S176
- medical nutrition therapy, **S177**
- noninsulin therapies, S176
- perioperative care, S177–S178
- physician order entry, S174
- quality assurance standards in, S174
- revisions summary, S6
- self-monitoring of blood glucose, **S177**
- stroke, S174
- type 1 diabetes, S176
- HOT trial, S105
- HPS2-THRIVE trial, S112
- Human NPH, S97
- human regular insulin, S97
- hydralazine, S106
- hyperbaric oxygen therapy, S134–S135
- hyperglycemia
- ARV-associated, S41
  - defined, S174
  - evaluation of, S40
  - exercise-induced, S149–S150
  - maternal, S22
  - postprandial as predictive, S66
  - posttransplant, S23
  - risk factors, S10
- hyperosmolar hyperglycemic state, S178
- hypertension, **S104–S113**
- antihypertensives, S104, S106–S108
  - bedtime dosing, S107
  - blood pressure targets, S104
  - children and adolescents, S153
  - chronic kidney disease and, S124, S128–S129
  - defined, S104
  - hyperkalemia/acute kidney injury, S107–S108
  - lipid management, **S109–S113**
  - meta-analyses of trials, S106
  - multiple-drug therapy, S107, S108
  - in older adults, S141
  - pharmacologic interventions, S107–S113
  - in pregnancy, S104, S106
  - randomized clinical trials, S104–S106
  - resistant, S108, S109
  - screening/diagnosis, S104
  - treatment algorithm, S108
  - treatment goals, S104
  - treatment strategies, S107–S113
  - treatment targets individualization, S106
- hypertriglyceridemia, S112

- hypoglycemia, **S66–S68**  
 A1C testing and, S62  
 anxiety disorders and, S42  
 cardiovascular disease and, S65  
 continuous glucose monitoring impacts, S75, S76  
 definitions, S67  
 exercise-induced, S53, S149–S150  
 hospital care, **S176–S177**  
 insulin therapy and, S91  
 moderate vs. tight glycemic control, S174–S175  
 in older adults, S67, **S140**, S145  
 postprandial, post-RYGB, S86  
 predictors of, S176  
 prevention, S68, S176–S177  
 pumps and, S73  
 recommendations, S66–S67  
 risk, evaluation of, S39, S40  
 risk factors, S10, S64  
 symptoms of, S67  
 treatment of, S67–S68  
 triggering events, S176
- hypoglycemia unawareness, S42, S66–S68
- IADPSG criteria, S22–S23
- idiopathic type 1 diabetes, S16
- IFG, S17
- immune-mediated diabetes, S16
- immunizations, S36–S39
- IMPROVE-IT trial, S111
- improvement. *see* quality of care
- incretin-based therapies, S143. *see also* DPP-4 inhibitors; GLP-1 receptor agonists
- Indian Diabetes Prevention Programme (IDPP-1), S31
- influenza vaccine, S36, S38
- inhaled insulin, S91, S97, S99
- injection-related anxiety, S42
- insulin pumps, S72–S73, S76, S91
- insulin resistance, S18
- insulin secretagogues, S143. *see also* sulfonylureas
- insulin syringes/pens, S71–S72
- insulin therapy  
 automated delivery, **S77**  
 basal insulin, S98–S99  
 carbohydrates and, S49, S50  
 children and adolescents, S156, S157  
 concentrated products, S97, S99  
 costs, S97–S99  
 critical care setting, S175  
 delivery technology, **S71–S73**  
 gestational diabetes mellitus, S167, S168  
 hospital care, S174–S176  
 hypoglycemia and, S91  
 indications, considerations, S93, S96–S97  
 inhaled insulin, S91, S97, S99  
 injection technique, S91  
 intravenous to subcutaneous transition, S176  
 noncritical care setting, S175–S176  
 older adults, S142–S143, S145  
 prandial insulin, S99  
 premixed insulin, S97, S99  
 type 1 diabetes, S90–S92  
 type 2 diabetes, S96, S98–S99
- insurance, S47, S77
- intermediate-acting insulin analogs, S97
- intermittently scanned CGM, S76–S77
- Internet-based DSMES, S47
- islet transplantation, S92
- JDRF CGM trial, S75, S76
- ketoacidosis. *see* diabetic ketoacidosis
- kidney disease. *see* chronic kidney disease
- Kumamoto Study, S64
- labetalol, S106
- language, S10, S35–S36
- laropiprant, S112
- Latinos  
 A1C variability in, S62  
 exercise targets in, S52  
 food insecurity in, S10  
 risk-based screening, S17, S18
- LEADER trial, S116–S118, S127, S128
- legacy effect, S66
- lifestyle management, **S46–S55**  
 cardiovascular disease, S115  
 children and adolescents, S156  
 cost effectiveness, S31  
 DSMES, S9, S10, **S31–S32**, **S46–S47**, S54  
 gestational diabetes mellitus, S167  
 hypertension, S107  
 medical nutrition therapy. *see* medical nutrition therapy  
 older adults, **S141–S142**  
 revisions summary, S4–S5  
 technology-assisted interventions, S31  
 type 2 diabetes prevention/delay, **S29–S31**  
 weight loss, S48–S51
- linagliptin, S96
- lipid management, **S109–S113**  
 children and adolescents, S153–S154, S159  
 combination treatment, S110–S112  
 HDL cholesterol, S109, S112, S159  
 LDL cholesterol, S109, S113, S159  
 lifestyle modification, S109  
 lipid profile/panel, S109  
 statins, S109–S113  
 triglycerides, S109, S112, S159
- lipohypertrophy, S91
- liraglutide, S85, S95, S97, S98, S116, S128
- Lispro 50/50, S97
- Lispro 75/25, S97
- Lispro, Lispro biosimilar, S97
- lixisenatide, S97, S116
- long-term care facilities, S144, S145
- Look AHEAD trial, S41, S82–S83
- Lorcaserin, Lorcaserin XR, S84
- loss of protective sensation (LOPS), S131, S134
- low-carbohydrate diets, S30, S48, S50
- macular edema, S129, S131
- MAO inhibitors, S83
- mature minor rule, S150–S151
- meal planning, S5, S48, S49
- medical evaluation, **S36–S39**  
 components of, S36–S38  
 immunizations, S36–S39  
 recommendations, S36  
 referrals, S40, S55
- medical nutrition therapy, **S47–S51**. *see also* nutrition  
 alcohol, S49, S51  
 carbohydrates, S49, S50
- children and adolescents, S149, S156
- eating patterns, S48–S50
- fats (dietary), S49–S51
- gestational diabetes mellitus, S167–S168
- goals of, S48
- herbal supplements, S49, S51
- hospital care, **S177**
- macronutrient distribution, S48–S50
- meal planning, S5, S48, S49
- micronutrients, S49, S51
- nonnutritive sweeteners, S5, S49, S51
- protein, S49, S50
- recommendations, S49
- sodium, S49, S51
- weight management, S48–S51
- Medicare, S47, S77
- medication adherence, S9
- medication reconciliation, S178
- Mediterranean diet, S30, S40, S48, S50, S51, S109
- meglitinides, S96
- mental health  
 children and adolescents, S150–S151, S159–S160  
 diabetes distress, S54–S55  
 evaluation of, S41–S42, **S54–S55**  
 homelessness, S10  
 illness, serious, S43, S55  
 issues, post-surgery, S86–S87  
 referrals, S40, S55
- metabolic memory, S66
- metabolic surgery  
 adverse effects, S86  
 benefits of, S86  
 children and adolescents, S158  
 indications, S86  
 obesity management, **S85–S87**  
 outcomes, S86  
 recommendations, S85–S86  
 referrals, S55
- metformin  
 cardiovascular disease, S114, S116–S118  
 children and adolescents, S156–S158  
 in chronic kidney disease, S127  
 costs, S96  
 gestational diabetes mellitus, S167, S168  
 indications, considerations, S93  
 initial therapy, S92–S97  
 older patients, S143  
 type 1 diabetes, S92  
 type 2 diabetes, S92  
 type 2 diabetes prevention/delay, **S31**  
 vitamin B12 deficiency and, S51, S92
- methylodopa, S106
- metoclopramide, S133
- micronutrients, S49, S51
- microvascular complications, S5, S63–S65, **S124–S135**. *see also* specific conditions
- migliol, S95
- MiG TOFU study, S168
- mineralocorticoid receptor antagonists, S109, S129
- MODY, S13, **S25**
- monogenic diabetes syndromes, S13, **S24–S25**
- multiple daily injections (MDI), S72–S73, S76, S91
- naltrexone/bupropion ER, S84
- nateglinide, S96
- neonatal diabetes, S24, **S25**
- nephropathy. *see* chronic kidney disease



- neuropathy, **S131–S133**. *see also* autonomic neuropathy; peripheral neuropathy
- characterization, S131
  - children and adolescents, S155, S158
  - diagnosis, S131–S132
  - distal symmetric polyneuropathy, S131
  - erectile dysfunction, S133
  - foot care, **S133–S135**
  - gastrointestinal, S132
  - gastroparesis, S133
  - neuropathic pain, S132, S133
  - orthostatic hypotension, S133
  - pharmacology, S132–S133
  - recommendations, S131
  - screening, S131
  - treatment, S131, S132
- niacin, S112
- NICE-SUGAR study, S174
- nifedipine, S106
- NODAT, S23
- nonalcoholic fatty liver disease (NAFLD), S4, S6, **S40**, S158–S159
- non-Hispanic whites. *see* Caucasians
- nonnutritive sweeteners, S5, S49, S51
- nonproliferative diabetic retinopathy, S53
- NPH/Regular 70/30, S97, S99, S175
- nucleoside reverse transcriptase inhibitors (NRTIs), S41
- nutrition. *see also* medical nutrition therapy
- medical evaluation of, S40
  - micronutrients, S49
  - obesity management, **S82–S83**
  - revisions summary, S4
  - type 2 diabetes prevention/delay, **S30**
- obesity management, **S81–S87**
- antihyperglycemics, S83
  - approved medications, S83–S85
  - assessment, **S81–S82**
  - behavioral therapy, **S82–S83**
  - benefits of, S81
  - cardiovascular disease and, S82
  - children and adolescents, S150, S155, S156
  - concomitant medications, S83
  - hypertension, S107
  - lipohypertrophy, S91
  - medical devices, S85
  - medical nutrition therapy, S48–S51
  - metabolic surgery, **S85–S87**
  - nutrition, **S82–S83**
  - pharmacotherapy, S83–S84
  - physical activity, **S82–S83**
  - pregnancy, S169
  - revisions summary, S5
  - treatment options, S82
  - type 2 diabetes, S82–S83
  - weight loss, S48–S51
- obstructive sleep apnea, S41, S158, S159
- olanzapine, S83
- older adults, **S139–S146**
- A1C in, S141, S142
  - aspirin and, S113–S114
  - complications, reduced functionality, S64, S141
  - DSMES, S141
  - frailty in, S141–S142
  - healthy, good functional status, S141, S142
  - hypertension in, S141
  - hypoglycemia in, S67, **S140**, S145
  - hypoglycemic admissions prevention, **S179**
  - insulin therapy, S142–S143, S145
  - lifestyle management, **S141–S142**
  - long-term care facilities, S144, S145
  - neurocognitive function, **S140**
  - pharmacology, S94, S96–S97, **S142–S145**
  - physical activity recommendations, S51
  - recommendations, S139
  - revisions summary, S6
  - screening, S139–S140
  - skilled nursing facilities, S144, S145
  - stroke in, S139, S142
  - treatment goals, **S140–S142**
  - treatment simplification/deintensification/deprescribing, S144
- one-step strategy, GDM, S21–S22
- oral glucose tolerance test (OGTT), S14, S20, S22
- orlistat, S84
- orthostatic hypotension, S133
- oxygen in meter accuracy, S74
- palliative/end-of-life care, S141, S144, **S146**
- pancreas transplantation, S92
- pancreatitis, S13, **S40**, S112, S116
- parenteral/enteral feedings, S177
- patient-centered care
- collaborative model of, **S34–S36**
  - pharmacology, S92, S93
  - population health, S7–S8
- PCSK9 inhibitors, S111, S113
- pediatrics. *see* children and adolescents
- periodontal disease screening, S41
- peripheral arterial disease, S133, S134
- peripheral neuropathy
- characterization, S131
  - diagnosis, S131–S132
  - micronutrients/supplements, S51
  - pharmacology, S31
  - physical activity and, S53
  - pre-exercise evaluation, S52–S53
  - treatment, S131
- pharmacology, **S90–S99**. *see also* specific medications, medication classes
- cardiovascular disease, S115–S119
  - cardiovascular disease outcomes, S98
  - children and adolescents, S156–S158
  - combination injectable, S99
  - combination therapy, S93–S94, S97–S98
  - costs, S96, S98
  - dual therapy, S92
  - gestational diabetes mellitus, S168
  - hypertension, S107–S113
  - initial therapy, S92–S97
  - injectables, S5, S97–S98
  - medication adherence, S9
  - medications as risk factor, S20
  - obesity management, S83–S84
  - older adults, S94, S96–S97, **S142–S145**
  - patient-centered care, S92, S93
  - patient factors, S5
  - revisions summary, S5
  - type 1 diabetes, **S90–S92**
  - type 2 diabetes, **S92–S98**
  - type 2 diabetes prevention/delay, **S31**
- phentermine, S84
- phentermine/topiramate ER, S84
- photocoagulation therapy, S129–S131
- physical activity, **S51–S53**
- autonomic neuropathy and (*see* autonomic neuropathy)
  - benefits, S52
  - children and adolescents, S51, S52, S149–S150, S156
  - DPP goals, S30
  - frequency/type of, S52
  - glycemic control and, S52
  - hypoglycemia and, S53
  - kidney disease, S50, S53
  - obesity management, **S82–S83**
  - peripheral neuropathy and (*see* peripheral neuropathy)
  - pre-exercise evaluation, S52–S53
  - recommendations, S51
  - retinopathy and, S53
  - revisions summary, S5
  - type 2 diabetes prevention/delay, **S30–S31**
- physician order entry, S174
- pioglitazone, S96
- pneumococcal pneumonia vaccine, S36, S38
- point-of-care meters, S175
- polycystic ovary syndrome, S159, S167, S168
- population health
- care delivery systems, **S8**
  - community screening, S20
  - defined, S7
  - patient-centered care, S7–S8
  - recommendations, S7
- posttransplantation diabetes mellitus, **S23–S24**
- pramlintide, S92, S96
- preconception counseling
- children and adolescents, S150, S151
  - contraception, S170
  - pregnancy, **S165–S166**
- prediabetes
- diagnosis, **S17–S20**
  - gestational diabetes mellitus, S170
  - HIV and, S41
  - physical activity recommendations, S51
  - serious mental illness and, S43
  - type 2 diabetes prevention/delay, **S30–S32**
- pregabalin, S132
- pregnancy, **S165–S170**
- A1C values in, S14, S15, S166, S167
  - antihypertensives and, S106
  - contraception, S170
  - diabetes, preexisting, **S168–S169**
  - diabetes risks in, S165
  - diabetic ketoacidosis, S169
  - drugs contraindicated, S106, S169
  - gestational diabetes mellitus, S6, S13, **S20–S23**, S76, **S167–S170**
  - glucose monitoring in, S166–S167
  - glycemic targets in, **S166–S167**, S169
  - hypertension in, S104, S106
  - insulin physiology in, S166
  - low-carbohydrate diets, S30, S48, S50
  - medical nutrition therapy, S48, S51
  - obesity management, S169
  - OGTT values in, S22, S169
  - postpartum care, **S169–S170**
  - preconception care, S166
  - preconception counseling, **S165–S166**
  - preeclampsia, S106, S167–S169
  - real-time CGM in, S76
  - retinopathy and, S129, S130
  - revisions summary, S6
- premixed insulin products, S97, S99, S175
- progestins, S83
- proliferative diabetic retinopathy, S53
- protease inhibitors (PIs), S41
- protein, S49, S50

- psychosocial/emotional disorders evaluation, S41–S42, **S54–S55**  
P2Y12 inhibitors, S113, S114  
pump. *see* insulin pump
- quality of care  
evaluation of, S9  
hospital care delivery standards, **S173–S174**  
quality assurance standards in, S174  
scientific evidence-grading system, **S2**  
system-level improvement strategies, S8
- ranibizumab, S129, S130  
rapid-acting insulin analogs, S97  
real-time CGM, S75–S76  
referrals, S40, S55, S129  
repaglinide, S96  
resistance exercise, S52  
retinal photography, S130  
retinal screening, S5  
retinopathy, **S129–S131**  
adjunctive therapy, S131  
anti-VEGF, S129–S131  
children and adolescents, S154–S155, S158–S159  
epidemiology, S129–S130  
macular edema, S129, S131  
photocoagulation therapy, S129–S131  
physical activity and, S53  
pregnancy and, S129, S130, S166  
proliferative, S130  
recommendations, S129  
screening, S129, S130  
treatment, S129–S131  
type 1 diabetes, S129, S130  
type 2 diabetes, S129, S130
- Risk Estimator Plus, S104  
risperidone, S83  
rosiglitazone, S96  
rosuvastatin, S111  
Roux-en-Y gastric bypass, S86
- SAVOR-TIMI trial, S117, S118  
saxagliptin, S96  
schizophrenia, S43  
school/child care, S150  
scientific evidence-grading system, **S2**  
scientific reviews, S2  
SEARCH study, S154  
self-monitoring of blood glucose (SMBG), **S73–S74**  
accuracy, S74, S75  
A1C testing and, S62  
basal insulin/oral agents, S73–S74  
glucose assessment by, S62–S63  
hospital care, **S177**  
intensive insulin regimens, S73  
optimization, S73  
recommendations, S73  
semaglutide, S96, S98, S116  
SGLT2 inhibitors  
cardiovascular disease and, S65, S92, S98, S114–S116  
in chronic kidney disease, S127, S128  
in combination therapy, S93–S94, S97–S98  
contraindications, S176  
costs, S96  
heart failure, S119  
hospital care, S176  
indications, considerations, S93  
low-carbohydrate eating plans and, S50  
older patients, S145  
stroke and, S115–S116  
type 1 diabetes, S92
- shoes, S134  
short-acting insulin analogs, S97  
sickle cell disease, S14  
simvastatin, S111  
sitagliptin, S96  
skilled nursing facilities, S144, S145  
sleep  
hypoglycemia prevention, S68, S170  
obstructive sleep apnea, S41, S158, S159  
pattern/duration assessment, S36  
pregnancy and, S170  
quality effects, S36
- smoking, S31, **S53–S54**, S154  
social determinants of health, **S9–S10**  
sodium, S49, S51  
sodium consumption, S5  
sotagliflozin, S92  
spironolactone, S106, S129  
SPRINT trial, S105–S106  
SSRIs, S83, S84  
statins  
cognition, effects on, S40  
cognitive function and, S113  
in combination treatment, S111, S112  
diabetes with, S112–S113  
dosing strategies, S111  
patients <40 years, S111–S112  
primary prevention, S110  
randomized trials, S110–S113  
recommendations, S109–S110  
risk-based therapy, S110  
secondary prevention, S111  
type 1 diabetes, S111–S112  
type 2 diabetes, S110
- stroke  
in children and adolescents, S158  
combination therapy and, S112  
CVD outcomes trials, S115–S117  
GLP-1 receptor agonists and, S116  
hospital care, S174  
hypertension treatment and, S105–S106  
ischemic, S112, S114  
in older adults, S139, S142  
risk reduction, S65, S105–S106, S111, S113  
screening, S114  
SGLT2 inhibitors and, S115–S116  
structured discharge communication, S178–S179  
sulfonylureas  
in combination therapy, S93–S94, S97–S98  
costs, S96  
gestational diabetes mellitus, S168  
indications, considerations, S93  
older patients, S143  
SUSTAIN-6 trial, S116–S118, S127  
sweeteners, S5
- tai chi, S51  
tapentadol, S132–S133  
TCAs, S83  
technology. *see also* continuous glucose monitoring (CGM); self-monitoring of blood glucose (SMBG)  
definitions, S71  
in diabetes management, **S71–S77**  
in diabetes prevention, S29, S31  
insulin pumps, S72–S73, S76, S91  
point-of-care meters, S175  
TECOS trial, S117, S118  
telemedicine, S4, S5, S8–S9, S31, S129  
temperature in meter accuracy, S74  
testosterone level evaluation, S41  
thiazolidinediones  
in combination therapy, S93–S94, S97–S98  
costs, S96  
heart failure, S118  
indications, considerations, S93  
older patients, S143  
in renal transplant recipients, S24  
type 2 diabetes prevention/delay, **S31**
- thought disorders, S43  
thyroid disease, S152  
tobacco use, S31, **S53–S54**, S154  
TODAY study, S157–S158, S160  
2-h plasma glucose (2-h PG), S14, S15  
two-step strategy, GDM, S21, S22  
type 1 diabetes  
albuminuria in, S127  
autoimmune conditions in, S152  
autoimmune diseases evaluation, S39  
cardiovascular disease and, S65  
celiac disease, S152–S153  
CGM in, S76  
in children and adolescents, S13–S14, **S148–S155**  
classification, S13–S14  
diagnosis, S15, **S16–S17**  
eating patterns, S48  
hospital care, S176  
idiopathic, S16  
noninsulin treatments, S91–S92  
pathophysiology, S14  
pharmacology, **S90–S92**  
physical activity benefits, S52  
preconception care, S166  
pregnancy, **S168–S169**  
recommendations, S16  
retinopathy, S129, S130  
risk screening, S16–S17  
staging, S14  
statins, S111–S112  
surgical treatment, **S92**  
thyroid disease, S152
- type 2 diabetes  
cancer evaluation, S39  
cardiovascular disease and, S65  
CGM in, S76  
children and adolescents, S17, S18, **S155–S160**  
chronic kidney disease and, S128  
classification, S13–S14  
combination therapy, S93–S94, S97–S98  
diagnosis, **S17–S20**, S155–S156  
DKA in, S18  
dyslipidemia in, S112  
insulin therapy, S95, S98–S99  
Internet-based DSMES, S47  
obesity management, S82–S83  
pathophysiology, S18  
pharmacology, **S92–S98**  
pharmacology, algorithm, S94  
pregnancy, **S168–S169**  
prevention/delay, **S29–S32**, S52  
retinopathy, S129, S130  
risk factors, S18, S20, S30  
screening/testing, S17–S20, S155

- statins, S110
- U-500 Human Regular insulin, S97
- UK Prospective Diabetes Study (UKPDS), S64, S66, S115
- vaccinations, S36–S39
- VADT study, S64, S65
- vitamin B12 deficiency, S31, S92
- vitamin C, S51
- vitamin E, S51
- water intake, S5
- weight loss. *see* obesity management
- whites. *see* Caucasians
- yoga, S51